These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 21134903

  • 1. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure.
    Gao D, Ning N, Niu X, Hao G, Meng Z.
    Heart; 2011 Feb; 97(4):278-86. PubMed ID: 21134903
    [Abstract] [Full Text] [Related]

  • 2. Metabolic modulation in heart failure: high time for a definitive clinical trial.
    Ashrafian H, Neubauer S.
    Heart; 2011 Feb; 97(4):267-8. PubMed ID: 21258118
    [No Abstract] [Full Text] [Related]

  • 3. Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis.
    Zhang L, Lu Y, Jiang H, Zhang L, Sun A, Zou Y, Ge J.
    J Am Coll Cardiol; 2012 Mar 06; 59(10):913-22. PubMed ID: 22381427
    [Abstract] [Full Text] [Related]

  • 4. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure.
    Fragasso G, Palloshi A, Puccetti P, Silipigni C, Rossodivita A, Pala M, Calori G, Alfieri O, Margonato A.
    J Am Coll Cardiol; 2006 Sep 05; 48(5):992-8. PubMed ID: 16949492
    [Abstract] [Full Text] [Related]

  • 5. Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure.
    Fragasso G, Salerno A, Lattuada G, Cuko A, Calori G, Scollo A, Ragogna F, Arioli F, Bassanelli G, Spoladore R, Luzi L, Margonato A, Perseghin G.
    Heart; 2011 Sep 05; 97(18):1495-500. PubMed ID: 21700755
    [Abstract] [Full Text] [Related]

  • 6. Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d'Abruzzo Trimetazidine Trial.
    Di Napoli P, Di Giovanni P, Gaeta MA, Taccardi AA, Barsotti A.
    J Cardiovasc Pharmacol; 2007 Nov 05; 50(5):585-9. PubMed ID: 18030070
    [Abstract] [Full Text] [Related]

  • 7. Metabolic modulation as a target for heart failure treatment: current perspective.
    Chenniapan S, Manchanda SC.
    Indian Heart J; 2007 Nov 05; 59(4):370-4. PubMed ID: 19126947
    [No Abstract] [Full Text] [Related]

  • 8. Surrogate end points in heart failure trials.
    Gheorghiade M, Adams KF, Gattis WA, Teerlink JR, Orlandi C, O'Connor CM.
    Am Heart J; 2003 Feb 05; 145(2 Suppl):S67-70. PubMed ID: 12594457
    [No Abstract] [Full Text] [Related]

  • 9. Role of trimetazidine in management of ischemic cardiomyopathy.
    Bertomeu-Gonzalez V, Bouzas-Mosquera A, Kaski JC.
    Am J Cardiol; 2006 Sep 04; 98(5A):19J-24J. PubMed ID: 16931202
    [Abstract] [Full Text] [Related]

  • 10. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure.
    Fragasso G, Perseghin G, De Cobelli F, Esposito A, Palloshi A, Lattuada G, Scifo P, Calori G, Del Maschio A, Margonato A.
    Eur Heart J; 2006 Apr 04; 27(8):942-8. PubMed ID: 16510466
    [Abstract] [Full Text] [Related]

  • 11. Trimetazidine and cardioprotection: facts and perspectives.
    Tsioufis K, Andrikopoulos G, Manolis A.
    Angiology; 2015 Mar 04; 66(3):204-10. PubMed ID: 24719262
    [Abstract] [Full Text] [Related]

  • 12. Trimetazidine: the future of cardiac function?
    Di Napoli P, Taccardi AA.
    Future Cardiol; 2009 Sep 04; 5(5):421-4. PubMed ID: 19715405
    [No Abstract] [Full Text] [Related]

  • 13. Is treatment with trimetazidine beneficial in patients with chronic heart failure?
    Zhou X, Chen J.
    PLoS One; 2014 Sep 04; 9(5):e94660. PubMed ID: 24797235
    [Abstract] [Full Text] [Related]

  • 14. Metabolic approach to heart failure - evidence that trimetazidine improves symptoms, left ventricular function and possibly prognosis.
    Jackson G.
    Int J Clin Pract; 2006 Aug 04; 60(8):891-2. PubMed ID: 16893429
    [No Abstract] [Full Text] [Related]

  • 15. Trimetazidine potentiates the effects of exercise training in patients with ischemic cardiomyopathy referred for cardiac rehabilitation.
    Belardinelli R, Lacalaprice F, Faccenda E, Volpe L.
    Eur J Cardiovasc Prev Rehabil; 2008 Oct 04; 15(5):533-40. PubMed ID: 18797405
    [Abstract] [Full Text] [Related]

  • 16. [Anti-ischemic effects of trimetazidine in patients with post-infarction heart failure].
    Tepliakov AT, Sankevich qV, Stepacheva TA, Garganeeva AA, Filippov EA, Pushnikova EIu, Kaliuzhin VV, Efimova I, Zavadovskiĭ KV.
    Klin Med (Mosk); 2004 Oct 04; 82(5):57-62. PubMed ID: 15230045
    [Abstract] [Full Text] [Related]

  • 17. Improved left and right ventricular functions with trimetazidine in patients with heart failure: a tissue Doppler study.
    Gunes Y, Guntekin U, Tuncer M, Sahin M.
    Heart Vessels; 2009 Jul 04; 24(4):277-82. PubMed ID: 19626400
    [Abstract] [Full Text] [Related]

  • 18. [Vasodilators in heart failure. Basis for their use].
    Mesquita ET, Mady C.
    Arq Bras Cardiol; 1994 Dec 04; 63(6):531-6. PubMed ID: 7605242
    [No Abstract] [Full Text] [Related]

  • 19. The effects of trimetazidine on heart rate variability in patients with heart failure.
    Gunes Y, Guntekin U, Tuncer M, Sahin M.
    Arq Bras Cardiol; 2009 Aug 04; 93(2):154-8. PubMed ID: 19838493
    [Abstract] [Full Text] [Related]

  • 20. Effects of trimetazidine on heart failure with reduced ejection fraction and associated clinical outcomes: a systematic review and meta-analysis.
    Nassiri S, Van de Bovenkamp AA, Remmelzwaal S, Sorea O, de Man F, Handoko ML.
    Open Heart; 2024 May 08; 11(1):. PubMed ID: 38719498
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.